Eli Lilly and Company (NYSE:LLY) Trading Down 0.1%

Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) were down 0.1% during mid-day trading on Monday . The stock traded as low as $731.10 and last traded at $732.79. Approximately 613,577 shares changed hands during trading, a decline of 79% from the average daily volume of 2,990,441 shares. The stock had previously closed at $733.51.

Analysts Set New Price Targets

LLY has been the topic of a number of recent research reports. Erste Group Bank upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Wednesday, April 3rd. Citigroup raised their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a "buy" rating in a report on Tuesday, April 2nd. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an "overweight" rating in a research report on Friday, March 15th. Truist Financial reaffirmed a "buy" rating and set a $850.00 price objective on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Finally, DZ Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating and set a $820.00 price objective on the stock. in a research note on Wednesday, February 21st. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $728.05.

Eli Lilly and Company Stock Performance

The company has a fifty day moving average price of $761.79 and a two-hundred day moving average price of $667.10. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The company has a market capitalization of $700.58 billion, a P/E ratio of 127.13, a PEG ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same period last year, the company earned $2.09 EPS. The firm's revenue was up 28.1% compared to the same quarter last year. Equities analysts forecast that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares of the company's stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.13% of the stock is currently owned by company insiders.

Institutional Trading of Eli Lilly and Company

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company's stock valued at $37,908,273,000 after purchasing an additional 659,838 shares during the period. Capital World Investors lifted its stake in Eli Lilly and Company by 0.3% in the fourth quarter. Capital World Investors now owns 26,949,773 shares of the company's stock valued at $15,709,466,000 after buying an additional 89,720 shares during the period. Morgan Stanley boosted its holdings in shares of Eli Lilly and Company by 0.7% during the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company's stock worth $6,738,605,000 after buying an additional 83,915 shares in the last quarter. Norges Bank acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $5,992,890,000. Finally, Northern Trust Corp increased its stake in shares of Eli Lilly and Company by 3.6% in the 3rd quarter. Northern Trust Corp now owns 10,158,275 shares of the company's stock valued at $5,456,314,000 after acquiring an additional 355,317 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.